Medicine guide
Eperzan
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Albiglutide
- Made by
- GlaxoSmithKline Trading Services Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: Monotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance. Add-on combination therapy In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | GlaxoSmithKline Trading Services Limited |
|---|---|
| Active substance | Albiglutide |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10BJ04 · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2014-03-20 |
| Last updated by the regulator | 2019-02-20 |
| EMA product number | EMEA/H/C/002735 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).